Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Neurotoxicology. 2018 Mar;65:68–84. doi: 10.1016/j.neuro.2018.01.009

Figure 3. Aminoimidazoaazarene treatment produces selective dopaminergic neurotoxicity.

Figure 3

Selective DA neuronal loss was detected for all tested aminoimidazoaazarene HCAs (IQ, MeIQ, MeIQx, 4,8-DiMeIQx, PhIP). The threshold dose required to elicit selective dopamine neuron toxicity is compound-dependent (A,C,E,G,I). Non-dopaminergic neurons are not affected at tested doses (B,D,F,H,J) as evidenced by undetectable changes in MAP2+/TH− cell counts. Cells were stained for TH (green) to identify dopamine neurons and MAP2 (red) to identify all neurons. The percentage of TH+ neurons to MAP2+ neurons (TH+ Neurons %) was calculated to determine DA neuronal loss. Data presented as the mean ± SEM; one way ANOVA with Dunnett’s post-hoc test, *p<0.05, **p<0.01, ***p< 0.001 compared to control. n = 6/group.